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Abstract 
Due to the increasing number of long-term cancer survivors, the ageing of the population, as well as the increased incidence and 
prevalence of oncologic and cardiovascular diseases, the number of patients presenting oncologic and cardiologic co-morbidities are 
increasing. Accordingly, there is a rapidly growing need for a comprehensive and proficient management of patients in whom the two co-
morbidities exist, and for cancer patients whose clinical history and oncologic treatment put them at higher risk for developing 
cardiovascular problems, in order to provide the optimal treatment in every situation, and to avoid the possibility that the development of 
the second disease does not lead to a reduction of therapeutic opportunities for the patient. A new discipline, cardio-oncology, has been 
created to deal with this need. Its aim is to investigate new strategies, collect new evidence-based indications and develop 
interdisciplinary expertise in order to manage this growing category of patients. Cardio-oncology deals with the following main clinical and 
research areas: early diagnosis of cardiotoxicity, risk stratification and preventions, treatment and monitoring of cardiotoxicity.
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The survival rate of patients with cancer, as well as those with 
cardiovascular disease has greatly increased over the past 
three decades [1,2,3]. This is partly due to improvements in 
pharmacological treatment and in surgery procedures and 
because of the reduction and control of major risk factors. On 
the other hand, due to the ageing of the population, the 
incidence and prevalence of oncologic and cardiovascular 
disease, as well as the number of patients presenting oncologic 
and cardiologic co-morbidities, are increasing. 
Because of overlapping risk factors, such as obesity, hormone 
replacement therapy and, in particular, smoking, heart disease 
patients are likely to have a higher risk of cancer than the 
general population [4,5].   
Conversely, the development of effective prevention screening 
and treatment strategies for many cancers, particularly in the 
early stages of the disease, has resulted in an enormous 
population of long-term cancer survivors. According to 
estimates from the National Cancer Institute and the Centres for 
Disease Control and Prevention, there were more than ten 
million cancer survivors in the United States alone in 2002 [6]. 
Many of these survivors have had radiation or chemotherapy 
(CT) treatments, with potential long-term cardiovascular 
toxicities, that may ultimately attenuate the clinical success of 
oncologic treatments. Data from recent oncology literature 
indicate that more than half of all patients exposed to 
chemotherapy will show some degree of cardiac dysfunction ten 
to 20 years after CT, 5% will develop overt heart failure, and 
40% will experience arrhythmias [7]. This population shows an 
eightfold higher cardiovascular mortality when compared to the 
general population [8]. 
For these reasons, there is a rapidly growing need for 
comprehensive and professional management aimed at patients 
in whom the two co-morbidities exist, and at cancer patients 
whose clinical history and oncologic treatment put them at 
higher risk for developing cardiovascular problems. This must 
be accomplished in order to provide optimal treatment in every 
situation, and to avoid the possibility that the onset of a second 
disease may lead to a reduction of therapeutic opportunities and 
negative long-term results. 
Indeed, when a cardiac patient develops an oncological 
problem, the cardiologist often loses interest in him or her and 
tends to inherit a defeatist attitude, which may exclude the 
patient from other intensive treatment and/or intervention 
possibilities. Conversely, when a cancer patient develops a 
cardiologic problem, he/she is invariably excluded from first-line, 
more aggressive (and therefore, more effective) therapeutic 
strategies, negatively impacting his oncologic outcome. 
The final result is that this patient goes beyond the jurisdiction of 
both the cardiologist and the oncologist, and there is no one 
who takes it upon himself to give this patient comprehensive 
care. As a consequence, the management of such patients is 
limited, disjointed and often inadequate. The patient feels left 
alone and unprotected. This behaviour may lead to negative 
prognostic influence during the course of the two illnesses, 
whereas, under different circumstances, the patient may have 
been effectively treated. 
In order to deal with this need, a new discipline, cardio-
oncology, has been created. Its aim is to investigate innovative 
strategies, collect evidence-based indications, and to develop 
interdisciplinary expertise, which will be able to manage this 
new and growing category of patients, to guarantee correct 
clinical administration, and to provide the best therapeutic 
opportunities, also in terms of the impact on prognosis of the 
two concomitant diseases, for these more complex patients. 
 
Diagnosis of cardiotoxicity 
Cardiotoxicity is a common complication of CT. The clinical 
manifestation of CT can range, in its more typical form, chronic 
cardiotoxicity, from transient asymptomatic left ventricular 
dysfunction to cardiac death [9,10]. 
This is a growing problem in the setting of clinical oncology, 
given the increasing number of long-term cancer survivors, the 
tendency to use progressively higher doses of anthracyclines 
(AC), the introduction of new anti-tumour agents with possible 
cardiotoxic properties and combined treatments with synergistic 
harmful effects [10–13]. The clinical implications of cardiotoxicity 
are particularly relevant in those cancer patients in whom the 
onset of cardiac dysfunction, even asymptomatic, seriously 
limits their therapeutic opportunities and negatively impacts their 
clinical outcome. Therefore, early identification of patients at risk 
for cardiotoxicity represents a primary goal for both cardiologists 
and oncologists, allowing for the definition of personalized 
antineoplastic therapeutic strategies and/or interventions [14].   
To detect CT-induced cardiac damage in an early phase, 
regular cardiac function assessment is, at present, 
recommended by oncologic guidelines. Cardiologic surveillance 
is required during CT, to allow for the administration of the 
highest dose without inducing cardiac injury, and after
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Figure 1: Left ventricular ejection fraction (LVEF) at baseline and during the seven months of follow-up of troponin I positive (TnI+) and 
negative (TnI-) patients.
completion of the CT to identify cardiac damage at an early 
preclinical stage. This is carried out in order to limit, by means 
of pharmacologic intervention, the progression of cardiac 
dysfunction. 
At least three international consensus guidelines recommend 
evaluation of left ventricular ejection fraction (LVEF) at the 
beginning of antineoplastic therapy, after administration of half 
the total anthracyclines cumulative dose, and before every 
following dose [15–17]. It is also recommended during follow-
up, and LVEF evaluation at three, six, and 12 months after the 
end of treatment [10,18]. A decline of LVEF by more than 10%, 
associated to an absolute LVEF value <50%, is suggested as a 
criterion for suspending treatment [19]. 
The weak point of such an approach is that it is too late. In fact, 
cardiac damage is usually detected when functional impairment 
has already occurred [20,21]. Many doubts have been raised 
about the utility of monitoring the cardiac function by LVEF 
evaluation by means of most utilized methods in clinical 
practice, including echocardiography and radionuclide-
angiocardiography, since the value of this monitoring seems to 
be neither sensitive nor specific enough to give an early 
prediction of the development of cardiac dysfunction after CT. 
Actually, it permits the identification of cardiac damage only 
after the onset of cardiac dysfunction, not allowing for any early 
strategy able to prevent future cardiomyopathy (CMP) [20]. On 
the other hand, the evidence of unaffected heart function does 
not exclude the possibility of further cardiac deterioration [22–
24]. 
Hence, there is growing expectation for newer, non-invasive 
and cost-effective diagnostic tools for the early identification of 
patients prone to developing drug-induced cardiotoxicity. 
In our clinical practice, we utilize different markers for the early 
identification of patients at increased risk of cardiotoxicity: 
troponin I and N-terminal-proB-type natriuretic peptide (NT-
proBNP). For both of these, an accurate predictive value has 
been demonstrated by our recent investigations. 
 
Markers of myocardial damage: troponin I 
Troponin I (TnI) is a protein present exclusively in the 
myocardial cells. The TnI plasma concentration is a well-
established, specific and sensitive marker of myocardial injury, 
widely used for the diagnosis and the risk stratification of acute 
coronary syndromes. More recently, TnI has been utilized to 
detect cardiac damage in other clinical settings, such as heart 
failure, acute pulmonary embolism, renal failure, sepsis and 
septic shock and stroke [25,26]. Evidence of troponin’s release 
after CT has previously been demonstrated in animal models 
and in clinical studies [27,28]. 
In previous studies, we demonstrated that TnI is a sensitive and 
specific marker of myocardial injury after high-dose CT, and that 
it is able to predict, in a very early phase, the development of 
future ventricular dysfunction, as well as its severity [29,30]. 
Indeed, patients showing an increase of this marker soon after 
the end of CT significantly decreased systolic ventricular 
function in the months following (Figure 1). Moreover, in our 
studies, we found a strong relationship between the maximal 
TnI value measured soon after CT and the degree of LVEF 
reduction during the follow-up (Figure 2). 
In a more recent work, a large population with a long follow-up 
(48 months) and a wide spectrum of cardiac events was
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Figure 2: Scatterplot of left ventricular ejection fraction (LVEF) changes against troponin I (TnI) value in TnI+ patients. Modified from Cardinale 
et al [29]. 
* = p<0.001 versus baseline (month 0); ﬂ = p<0.001 versus TnI-group. Data are shown as mean ±95% CI. 
 
 
Figure 3: Early and late troponin I (TnI) values in the three study groups. 
*p<0.05 versus early TnI; **p<0.001 versus early TnI; ﬂ=p<0.001 versus TnI+/-; #p<0.001 versus TnI-/-. From Cardinale et al [31] 
considered [31]. As in the previous studies, we evaluated TnI at 
baseline and in the first 72 hours after CT (early TnI); in 
addition, in all patients, we also measured TnI one month later 
(late TnI). Three different TnI patterns were identified in our 
population (Figure 3): in most patients (70%), an early and late 
negative TnI value was found. In 21%, TnI increased soon after 
CT and normalized one month later. In the remaining 9% of 
patients, TnI positivity was still detectable one month later. 
 4  www.ecancermedicalscience.com 
R
e
v
i
e
w
secancer 2008, 2:126 
 
 
 
Figure 4: Scatterplot of N-terminal-proB-type natriuretic peptide (NT-proBNP) value at 72 hours against left ventricular ejection fraction (LVEF) 
changes at 12 months versus baseline.
The TnI behaviour after CT allowed for the identification of a 
different cardiac risk, according to the three distinct TnI 
patterns. Patients without TnI elevation after CT had a good 
prognosis. Indeed, no significant reduction in LVEF was 
observed in this group, and a very low incidence of cardiac 
events (1%) occurred during the more than three-year long 
follow-up. Hence, in consideration of the high-negative 
predictive value of troponin (99%), low-risk patients (70% of 
patients in this study) that do not require close cardiac 
surveillance after CT may accurately be identified. In contrast, 
TnI positive patients had a greater incidence of major adverse 
cardiac events. Among TnI positive patients, the persistence of 
the TnI increase one month after CT is consistent with a greater 
cardiac impairment and a higher incidence of cardiac events 
than in patients showing only a transient increase (84% and 
37%, respectively; p<0.001) [31]. 
TnI increase is also detectable in patients undergoing standard 
dose of chemotherapy. Experience in our institute shows 
increased TnI value in 20% of patients treated with schedules 
containing adriamycin-cyclophosphamide (AC); however, TnI 
increases, even less frequently (10–15%), also after the 
administration of schemes considered less cardiotoxic. More 
recently, we found TnI increase also in patients treated with 
monoclonal antibodies (20%, 5% and 8% in trastuzumab, 
bevacizumab and rituximab treated patients, respectively). In all 
patients, the prognostic relevance of TnI increase, in terms of 
LVEF reduction, was confirmed. In our view, TnI can be 
proposed as a golden standard marker for the assessment of 
cardiac safety of both old and new antineoplastic treatments, 
regardless of the mechanism underlying the cardiac toxic effect. 
Haemodynamic markers: NT-proBNP 
Natriuretic peptides have recently emerged as biomarkers 
potentially useful in the diagnosis and prognostic stratification of 
patients with heart failure. Particularly, NT-proBNP is released 
from the heart in response to a cardiac overload [32]. 
We evaluated the usefulness of NT-proBNP as an early marker 
able to predict cardiac dysfunction in patients affected by 
aggressive malignancies who were treated with high-dose CT 
[33]. We found three distinct NT-proBNP concentration patterns. 
Thirty-one per cent of patients had no changes in NT-proBNP 
concentrations during the six samples taken in the 72 hours 
after CT; 35% of patients had only a transient increase, with 
concentrations normalizing at 72 hours. In all these patients, no 
significant echocardiographic changes were recorded during 
follow-up. Thirty-three per cent of patients with persistently 
increased NT-proBNP concentrations at 72 hours developed a 
significant worsening of both diastolic and systolic properties 
values during the 12 months of observation. In particular, the 
echocardiographic monitoring revealed significant increases in 
mitral deceleration time, in isovolumetric relaxation time and in 
mitral E/A ratio. LVEF mean value decreased from 62.8% to 
45.6% (p<0.001). We also found a strong relationship between 
NT-proBNP value at 72 hours, and LVEF changes at 12 months 
versus baseline (Figure 4). 
Like TnI, NT-proBNP seems able to give us two kinds of 
information; the first is qualitative: it is able to identify patients 
who will develop cardiac dysfunction after CT; the second is 
quantitative: the absolute value of NT-proBNP at 72 hours 
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Figure 5: Left ventricular ejection fraction (LVEF) at baseline (before chemotherapy) and during 12-month follow-up in enalapril patients (solid 
bars) and controls (open bars). B = baseline; R = randomization to enalapril or no therapy (one month after chemotherapy); p value for repeated 
measures analysis of variance < 0.001.
reflects the degree of the future left ventricular impairment. The 
innovative aspect of these markers is that they give us this 
information at a very early phase, soon after the CT 
administration, and long before a functional impairment has 
occurred and could be identified by diagnostic techniques such 
as echocardiography. 
Further prospective studies are needed to clarify whether both 
markers, TnI I and NT-proBNP, give the same kind of 
information, or whether their combination permits better 
stratification of the cardiac risk of cancer patients treated with 
CT. 
Cardiotoxicity prevention: a new 
prophylactic approach 
The possibility of identifying patients at higher risk of developing 
cardiotoxicity by cardiac biomarkers provides a rationale for the 
development of targeted preventive pharmacological strategies 
directed at counteracting cardiac dysfunction and cardiac 
complications occurrence. 
Considering the results of our published studies, a possible 
clinical application of these markers could be the evaluation of 
pharmacological strategies in selected high-risk patients, with 
the aim of preventing acute cardiac damage, left ventricular 
dysfunction and cardiac events. Two different therapeutic 
strategies could be implemented in order to reduce the clinical 
impact of cardiotoxicity: (1) use of specific cardiologic 
treatments given to cancer patients during CT in the attempt to 
prevent or blunt the rise of these markers; (2) use of cardiologic 
treatments given only to selected cancer patients, showing an 
increase in these markers after CT. This, with the aim of 
interfering with the natural evolution of cardiac toxicity and 
prevent the occurrence of left ventricular dysfunction and 
adverse cardiac events. We hypothesize that cardioprotective 
therapies that might limit or prevent marker rise after CT, as well 
as cardiologic treatments that interfere with their persistence, 
could improve cardiac prognosis of these patients. 
Angiotensin-converting enzyme inhibitors (ACEI) have been 
shown to slow the progression of left ventricular dysfunction in 
several different clinical settings, including AC-induced CMP 
[34,35]. Furthermore, data referring to experimental models 
suggest that the cardiac renin-angiotensin system (RAS) plays 
an important role in the development of AC-induced CMP, and 
that treatment with ACEI may protect against CT-induced 
cardiotoxicity [36–41]. According to these data, a prophylactic 
strategy based on the use of ACEI could prevent cardiotoxicity 
in selected high-risk patients. 
In a recent study from our institute, 473 consecutive cancer 
patients undergoing high-dose CT were evaluated; of them, 114 
(24%) showed TnI increase soon after CT and were 
randomized, either to receive enalapril (ACEI-group, n=56), or 
not (controls, n=58) [42]. Treatment, started one month after 
CT, was continued for one year. In ACEI-group, LVEF did not 
change during the treatment period (Figure 5), and a lower 
incidence of adverse cardiac events was observed (Table 1). 
The LVEF was also analysed separately in patients with only 
transient TnI increase, and in those with persistent increase. In
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Table 1: Cardiac events during the one-year follow-up in enalapril-treated patients and in controls (modified from Cardinale et al [42]) 
 
 
Figure 6: Left ventricular ejection fraction at baseline and during the 12 month follow-up in controls (left panel) and in ACEI-group (right panel), 
in patients with (open squares) or without (solid squares) persistent troponin I (TnI) increase (R = randomization). 
*p<0.001 versus baseline and randomization for all time points; # p<0.001 versus patients without persistent TnI increase. p value for treatment effect 
<0.001. p value for effect of persistent TnI increase <0.001. p value for interaction between treatment and persistent TnI increase < 0.001. (From 
Cardinale et al [42])
agreement with previous findings [31], untreated patients with a 
persistent (one month after the end of CT) TnI increase had a 
greater long-term LVEF reduction than patients with only 
transient TnI increase (LVEF decreased from 62% to 43% in the 
former group and from 63% to 57% in the latter; p<0.001). In 
treated patients, the benefit of enalapril was present in both 
subgroups: in no patient was LVEF significantly changed (from 
61% to 62% and from 62% to 61%, respectively; p=NS), 
confirming that patients with persistent TnI increase are at 
particularly high risk of cardiotoxicity and may particularly 
benefit from this preventive therapy (Figure 6) [42]. 
Although the underlying mechanisms by which ACEI may 
prevent cardiotoxicity and improve outcome in high-risk CT-
treated patients are not completely clear, the induction of a 
more favourable haemodynamic condition and RAS activation
 7  www.ecancermedicalscience.com 
R
e
v
i
e
w
secancer 2008, 2:126 
 
 
Figure 7: Left ventricular ejection fraction at baseline and 12 months after chemotherapy in troponin I positive patients (TnI+) treated with 
enalapril and troponin I negative patients (TnI -).
counteraction are likely to play crucial roles. Local inhibition of 
cardiac ACE could also be involved. Data referring to 
experimental models suggest that cardiac RAS plays an 
important role in the development of AC-induced CMP, and that 
beneficial effects of ACEI in AC-treated animals depends on 
inhibition of cardiac ACE [36–41]. Moreover, treatment with 
lisinopril, started after the end of CT, significantly inhibited 
cardiac ACE activity and improved mortality, cardiac 
remodelling and cardiac dysfunction in an animal model [36]. 
Finally, increased oxidative stress has been indicated as a 
possible primary mechanism in the development of AC-induced 
cardiac toxicity, and ACEI have been shown to exert antioxidant 
effects by scavenging free radicals [38]. 
After this study experience, we applied the new strategy to our 
daily clinical practice in our institute. The results are 
summarized in Figure 7. We considered more than 300 
patients, we found TnI positivity in 20% of patients and we 
started treatment with enalapril in all cases. In patients without 
increase of the marker, we did not perform any preventive 
treatment, and, as expected, no significant changes in LVEF 
occurred during one-year follow-up. Similarly, in patients 
showing an early TnI increase, we did not observe a significant 
reduction of systolic function. This finding confirms that 
cardiotoxicity can effectively be prevented in high-risk patients 
with this approach, and this preventive strategy can be easily 
applied in daily clinical practice. 
Cardiotoxicity treatment and monitoring 
The most common clinical presentation of cardiotoxicity is a 
dose-dependent CMP leading to chronic heart failure (HF), 
frequently occurring after administration of CT including AC 
[10,11]. 
The prevalence of CT-induced CMP is not well known, as most 
studies and registries have not specifically analysed this CMP 
among the several possible causes of acute and chronic HF. 
From among the few studies in which the aetiology of HF has 
been evaluated in detail, a prevalence of 1% of all cases of 
CMP has been reported [43,44]. However, as reported 
previously, data from recent oncology literature indicate that 
more than half of all patients exposed to AC will show some 
degree of cardiac dysfunction ten to 20 years after CT, and 5% 
will develop overt HF. As more than 60,000 patients are treated 
every year with AC in the United States, the overall incidence of 
this complication is probably greatly underestimated [7]. 
Moreover, patients with CMP due to AC are usually considered 
to have an especially poor prognosis, in comparison with other 
more frequent forms of CMP [43], with a long-term mortality, 
such as ischemic and primitive CMP. The relative risk of death 
in patients with AC-induced CMP is reported as 2.6-fold greater 
than primitive CMP. 
Historically, CT-induced CMP is believed to be refractory to 
conventional therapy, but many of these data are anecdotal and 
 8  www.ecancermedicalscience.com 
R
e
v
i
e
w
secancer 2008, 2:126 
 
are based on reports including small numbers of patients. In 
addition, cancer patients with CT-induced CMP have 
systematically been excluded from large randomized trials 
evaluating the efficacy of recommended HF therapy. 
As a consequence, evidence-based recommendations for 
management of cancer patients with asymptomatic and 
symptomatic CT-induced CMP are still lacking, and no definite 
guidelines are currently adopted. In particular, there is no 
evidence as to whether the use of ACEI and beta-blocker 
agents, recommended by international cardiologic guidelines for 
treatment of HF, can be directly transferred with similar long-
term benefits to this particular setting. 
In addition, it is very difficult to obtain evidence-based 
indications from the existing literature, as only an overall adult 
population of 108 patients can be derived from a total of 11 
previous publications, mostly retrospective, without predefined 
end points, and in which a non-uniform treatment was 
considered [20,43–52]. 
In these studies, most patients were treated with digitalis and 
diuretics, 30% of patients were treated with ACEI, 5% with beta-
blockers, and only 23% of patients received a combination of 
beta-blockers and ACEI. Therefore, even if in some cases 
patients experienced an improvement of systolic function and 
relief of symptoms, the anecdotal nature of these observations 
does not allow us to derive clear indications, in terms of defining 
the best therapeutic strategy for this form of CMP. 
Furthermore, an open critical question remains: whether or not 
to treat cancer patients with asymptomatic left ventricular 
dysfunction [7,20,43–52]. 
Due to the different aetiology and age distribution of this kind of 
CMP, when compared with the more frequent ischemic or 
idiopathic CMPs, there is some concern as to whether the use 
of ACEI and beta-blocking agents can be directly applied to a 
cancer patient setting. One of the trickier aspects of the late 
cardiac dysfunction associated with AC is the early 
asymptomatic nature of the disease. Given the silent nature of 
the underlying state, many authors have suggested only 
screening programmes to look for overt HF, and, at present, 
CT-induced CMP patients are treated only if symptomatic. A 
crucial issue is whether or not, and eventually how, to treat 
asymptomatic patients in whom left ventricular dysfunction is 
detected on routine screening examinations. To date, there is 
no consensus about what (if anything) can be done to curtail the 
progression of CT-induced CMP [7]. It is likely that the typical 
medications used for HF are highly effective, but there may be 
special concern in cancer patients and, conventionally, the 
tendency is not to treat aggressively [53]. 
Preliminary unpublished data from our institute suggest that the 
time elapsed from the end of CT to the start of HF therapy, with 
ACEI and, when tolerated, with beta-blocking agents, is a 
crucial variable for recovery of cardiac dysfunction. Indeed, the 
likelihood of obtaining a complete LVEF recovery is higher in 
patients in whom the treatment is initiated within two months 
from the end of CT. After this time limit, however, this 
percentage progressively decreases and no complete LVEF 
recovery is observed after six months. 
On the basis of these data, we can speculate that, in most 
previously published studies, the poor response to therapy was 
possibly due to the under-use of modern drugs like ACEI and 
beta-blocking agents, and to the long (>12 months) time 
elapsed from the end of CT to the beginning of cardiac 
treatment, that is, when cardiac damage was no longer 
reversible. This emphasizes the crucial importance of an early 
detection of cardiotoxicity and suggests that an aggressive 
approach based on the association of both ACEI and beta-
blocking agents should always be considered, and attempted, in 
all cases of CT-induced CMP. 
Although preventing AC-induced cardiotoxicity remains the 
optimal target, cardiac function should also be monitored, in 
patients receiving potentially cardiotoxic CT, in order to detect 
early cardiac abnormalities while they are still reversible. 
Indeed, the American College of Cardiology, the American 
Heart Association, and the American Society of 
Echocardiography recommend baseline routine evaluations and 
recurrent re-evaluations by echocardiography in patients 
undergoing CT [54]. However, this recommendation is often 
disregarded in asymptomatic patients and in those recovered 
from the oncologic disease. Oncologists and cardiologists 
should plan these assessments jointly, sharing therapy 
decisions and monitoring programmes, in order to prevent both 
potentially fatal oncologic and cardiologic diseases.  
  
Cardio-oncology: conclusion  
Cardio-oncology is a novel, interdisciplinary, rapidly evolving 
area of growing interest, based on a comprehensive approach 
for the management of cancer patients with cardiac diseases. 
Due to the lack of evidence-based indications and to the urgent 
need for expertise in this setting, cardio-oncology represents a
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novel, topical research and clinical field, largely unexplored. 
Involved clinicians and researchers have the ambitious task of 
investigating this setting, outlining new evidence-based
guidelines. This represents a big challenge for both 
cardiologists and oncologists, and, at the same time, is a 
stimulating incentive. 
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